Avita Medical stock gained 5.91 percent near its yearly high

Published on 10/05/2026 at 13:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Avita Medical stock is backed by 2026 revenue guidance of USD 86 million to USD 89 million, raised on September 16, 2026. Q2 revenue reached USD 21.7 million.

RCEL, AU000000AVH4, Illustration mit AI erstellt.

Avita Medical (ISIN AU000000AVH4) was last at USD 12.72 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, up 5.91 percent from the prior close. The move brought the stock to USD 12.76 at the session high and close to its 52-week high of USD 12.76, giving the latest market action a clear earnings and guidance backdrop.

Revenue guidance moves higher

According to Investing.com on September 16, 2026, AVITA Medical raised its 2026 revenue guidance to USD 86 million to USD 89 million from USD 80 million to USD 85 million. The new range implies a higher sales ceiling and places execution, reimbursement stability and product adoption at the center of the investment case.

The same Investing.com report said second-quarter cash burn fell to USD 3.2 million and management expects cash flow breakeven in the fourth quarter. RECELL gross margin was reported at 86 percent, while overall gross margin was expected to remain above 80 percent.

Q2 revenue beats consensus

MarketBeat reported on September 13, 2026 that AVITA generated Q2 revenue of USD 21.7 million against a USD 20.25 million consensus estimate, a 7.2 percent beat. Adjusted loss per share was USD 0.25, narrower than the USD 0.29 consensus loss by USD 0.04.

The revenue result matters because the company entered the second half with sequential growth as a stated operating priority. AVITA also has a cost-control milestone ahead: management said quarterly operating expenses were USD 24 million and that the business could reach cash flow breakeven in Q4, while the second-quarter cash burn stood at USD 3.2 million.

Consensus target trails latest price

MarketBeat listed a Moderate Buy consensus from seven analysts, comprising five buys, one hold and one sell, with an average 12-month price target of USD 11.40. The latest price of USD 12.72 was 11.6 percent above that average target, making the market response more demanding than the published consensus view.

TradingView lists November 5, 2026 as the next earnings date. That report will give investors a fresh test of the USD 86 million to USD 89 million full-year guidance range and the path toward fourth-quarter cash flow breakeven.

Stock reaches yearly high

Avita Medical stock was last at USD 12.72 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, with a 52-week range of USD 3.22 to USD 12.76 and market capitalization of USD 316.0 million.